

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 May 2022 (05.05.2022)



(10) International Publication Number
WO 2022/089604 A1

(51) International Patent Classification:

C07D 231/02 (2006.01) A61K 31/415 (2006.01)
A61K 31/4155 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CN2021/127601

(22) International Filing Date:

29 October 2021 (29.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/125425
30 October 2020 (30.10.2020) CN
PCT/IB2020/062144
17 December 2020 (17.12.2020) IB
PCT/CN2021/101813
23 June 2021 (23.06.2021) CN

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventor; and

(71) Applicant (for SC only): **LIU, Bo** [CN/CN]; China Novartis
Institutes For Biomedical Research Co., Ltd., 4218 Jinke
Road, Pudong New Area, Shanghai 201203 (CN).

(72) Inventors: **COTESTA, Simona**; Novartis Pharma AG,
Postfach, 4002 Basel (CH). **GE, Heng**; Suzhou Novartis
Technical Development Co., Ltd., #18-1, Tonglian Road,
Bixi Subdistrict, Changshu, Jiangsu 215537 (CN). **GERS-
PACHER, Marc**; Novartis Pharma AG, Postfach, 4002
Basel (CH). **LEBLANC, Catherine**; Novartis Pharma AG,
Postfach, 4002 Basel (CH). **LORTHIOIS, Edwige Lil-
iane Jeanne**; Novartis Pharma AG, Postfach, 4002 Basel
(CH). **MACHAUER, Rainer**; Novartis Pharma AG, Post-
fach, 4002 Basel (CH). **MAH, Robert**; Novartis Pharma
AG, Postfach, 4002 Basel (CH). **MEISTER, Tanja**; No-
vartis Pharma AG, Postfach, 4002 Basel (CH). **MURA,
Christophe**; Novartis Pharma AG, Postfach, 4002 Basel
(CH). **RIGOLLIER, Pascal**; Novartis Pharma AG, Post-
fach, 4002 Basel (CH). **SCHNEIDER, Nadine**; Novartis
Pharma AG, Postfach, 4002 Basel (CH). **STUTZ, Stefan**;
Gundeldingerrein 53, 4059, Basel (CH). **VAUPEL, An-
drea**; Novartis Pharma AG, Postfach, 4002 Basel (CH).
WARIN, Nicolas; Novartis Pharma AG, Postfach, 4002
Basel (CH). **WILCKEN, Rainer**; Novartis Pharma AG,
Postfach, 4002 Basel (CH). **XUE, Lijun**; Suzhou Novartis
Technical Development Co., Ltd., #18-1, Tonglian Road,
Bixi Subdistrict, Changshu, Jiangsu 215537 (CN).

(74) Agent: **ZHONGZILAW OFFICE**; 7F, New Era Building,
26 Pinganli Xidajie, Xicheng District, Beijing 100034 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NEW CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND

(57) Abstract: Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment of cancer, and KRAS G12C-mutant cancer.

WO 2022/089604 A1